Compare SLNH & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | VTVT |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.9M | 148.7M |
| IPO Year | N/A | 2015 |
| Metric | SLNH | VTVT |
|---|---|---|
| Price | $1.84 | $30.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 20.1M | 42.0K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $14.00 |
| 52 Week High | $5.14 | $44.00 |
| Indicator | SLNH | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 38.88 |
| Support Level | $1.78 | $30.15 |
| Resistance Level | $2.29 | $33.11 |
| Average True Range (ATR) | 0.27 | 2.57 |
| MACD | 0.03 | -0.32 |
| Stochastic Oscillator | 89.08 | 16.19 |
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.